---
title: "Fulcrum Therapeutics director Alan Ezekowitz disposes of 18,000 common shares for $65,614"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291330614.md"
description: "Fulcrum Therapeutics director Alan Ezekowitz sold 18,000 common shares on June 26, 2026, at a weighted average price of $3.65 per share, totaling $65,614. Following the transaction, Ezekowitz retained 10,927 shares. The disclosure was published via EDGAR on June 30, 2026."
datetime: "2026-06-30T20:30:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291330614.md)
  - [en](https://longbridge.com/en/news/291330614.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291330614.md)
generator: "portal-rs"
---

# Fulcrum Therapeutics director Alan Ezekowitz disposes of 18,000 common shares for $65,614

-   Fulcrum Therapeutics director Alan Ezekowitz sold 18,000 common shares on June 26, 2026. \* Shares sold at a weighted average price of $3.65. \* Ezekowitz held 10,927 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290622), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FULC.US](https://longbridge.com/en/quote/FULC.US.md)

## Related News & Research

- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [FULC: Merger forms a well-funded migraine biotech with clinical milestones expected through 2029](https://longbridge.com/en/news/296111857.md)
- [Fluidra buys back 259,500 shares Aug 18-21 at average price 19.15](https://longbridge.com/en/news/296870067.md)
- [Fleury board holding increases by R$ 70,053.75 after on-market share buy](https://longbridge.com/en/news/296728002.md)
- [KER Holding, linked to Clariane director HLD Europe, purchases EUR 0.27 million of Clariane shares](https://longbridge.com/en/news/296938133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**